Some researchers theorize that tirzepatide's biased agonism, particularly its stronger GIP activity relative to GLP-1 activity, may produce a different side effect profile that certain people tolerate better
GLP-1 (Glucagon-like peptide-1) and GLP-1/GIP (Glucose-dependent Insulinotropic Polypeptide) agonists, FDA-approved for managing type 2 diabetes and obesity, where the former has shown to effectively reduce the consumption of alcohol in animal models but no reports exist on the latter
For instance, if youve recently taken a specific medication or undergone a medical procedure, you might be temporarily deferred
Because tirzepatide adds GIP receptor activity to GLP-1 activity, it can be a logical next step when semaglutide hasn't produced enough benefit, but the right move depends on your dose history, tolerability, and goals, which is why we evaluate it case by case
Liu S, et al